Guggenheim Maintains Buy on Genmab, Raises Price Target to $54

Benzinga Newsdesk www.benzinga.com Positive 70.4%

Neg 0% Neu 0% Pos 70.4%

Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $54.